NetworkNewsBreaks – Imagin Medical Inc. (CSE: IM
Post# of 31
(Total Views: 154)
Posted On: 05/19/2021 3:52:02 PM
NetworkNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Announces On-Track Progress for Demonstration of i/Blue Imaging System(TM)
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Per the update, the company is on target to demonstrate the i/Blue Imaging System(TM) in private meetings during the American Urology Association (“AUA”) meeting to be held in early September. The product will showcase updates to meet performance criteria against competitive products and enhancements made to the design for manufacturing. “As the process moves forward, we’re creating the potential for additional IP that will make the i/Blue Imaging System unique and innovative and strengthen the demand for blue light cystoscopy (‘BLC’),” said Jim Hutchens, Imagin’s president and CEO. “Patients have been hearing about the superiority of blue light over white light to identify bladder cancer tumors and are searching for facilities that provide it.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Per the update, the company is on target to demonstrate the i/Blue Imaging System(TM) in private meetings during the American Urology Association (“AUA”) meeting to be held in early September. The product will showcase updates to meet performance criteria against competitive products and enhancements made to the design for manufacturing. “As the process moves forward, we’re creating the potential for additional IP that will make the i/Blue Imaging System unique and innovative and strengthen the demand for blue light cystoscopy (‘BLC’),” said Jim Hutchens, Imagin’s president and CEO. “Patients have been hearing about the superiority of blue light over white light to identify bladder cancer tumors and are searching for facilities that provide it.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)